Jordheim Lars Petter
Univ Lyon, Université Claude Bernard Lyon 1, INSERM 1052, CNRS 5286, Centre Léon Bérard, Centre de Recherche en Cancérologie de Lyon, 69008 Lyon, France.
Cancers (Basel). 2023 Feb 3;15(3):997. doi: 10.3390/cancers15030997.
PARP inhibitors are small molecules currently used with success in the treatment of certain cancer patients. Their action was first shown to be specific to cells with DNA repair deficiencies, such as BRCA-mutant cancers. However, recent work has suggested clinical interest of these drugs beyond this group of patients. Preclinical data on relationships between the activity of PARP inhibitors and other proteins involved in DNA repair exist, and this review will only highlight findings on the SLX4 protein and its interacting protein partners. As suggested from these available data and depending on further validations, new treatment strategies could be developed in order to broaden the use for PARP inhibitors in cancer patients.
聚（ADP-核糖）聚合酶（PARP）抑制剂是目前成功用于治疗某些癌症患者的小分子药物。它们的作用最初被证明对存在DNA修复缺陷的细胞具有特异性，例如BRCA突变型癌症。然而，最近的研究表明，这些药物在这类患者群体之外也具有临床应用价值。目前已有关于PARP抑制剂活性与其他参与DNA修复的蛋白质之间关系的临床前数据，本综述将仅重点介绍关于SLX4蛋白及其相互作用蛋白伙伴的研究结果。根据这些现有数据并有待进一步验证，有望开发出新的治疗策略，以扩大PARP抑制剂在癌症患者中的应用范围。
